Monkey pox has made international headlines this summer. WHO Director-General declares mpox outbreak a public health emergency of international concern.
➡ https://lnkd.in/dhjPxf9c
As of August 2024, Mpox remains a global health concern following its recent resurgence. The World Health Organization (WHO) has issued warnings due to increasing case numbers in various regions, including significant outbreaks in both endemic and non-endemic countries. Efforts to manage the situation include vaccination campaigns, enhanced surveillance, and research into more effective treatments and diagnostics. Public health responses are focused on containment and preventing further spread.
Benchmark Antibodies is pleased to offer a range of life science reagents specifically designed for Mpox research and diagnostics. Our products are engineered to support accurate and efficient testing.
Benchmark’s application validated Mpox catalogue reagents provide:
• Reliable monoclonal antibodies for ELISA, WB and IHC applications
• High purity recombinant proteins validated by HPLC and PAGE analysis
• Rapid 1-2 day order fulfillment from North American inventory
• Optimal pricing
• Retained lots for phased bulk ordering
hashtag#Monkeypox hashtag#MonkeypoxVirus hashtag#MPXV hashtag#B6R hashtag#A29L hashtag#A30L hashtag#E8L hashtag#M1R hashtag#A35R hashtag#A5L hashtag#H3L hashtag#Mpox hashtag#Immunodiagnosis hashtag#WHO hashtag#Mpox hashtag#PublicHealth hashtag#Epidemiology hashtag#HealthAwareness hashtag#InfectiousDiseases hashtag#IVD
